GlycoMimetics to Receive European Patent for GMI-1271
"The European Patent Office's issuance of patent rights covering
GMI-1271 underscores the progress we've made in protecting our
intellectual property and innovative pipeline," said
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease. GlycoMimetics' most advanced drug
candidate, rivipansel, a pan-selectin antagonist, is being developed for
the treatment of vaso-occlusive crisis in sickle cell disease and is
being evaluated in a Phase 3 clinical trial being conducted by its
strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug
candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an
ongoing Phase 1/2 clinical trial as a potential treatment for AML and in
a Phase 1 clinical trial in multiple myeloma. The
Forward-Looking Statements
This press release contains forward-looking statements regarding
View source version on businesswire.com: http://www.businesswire.com/news/home/20170706005056/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media